MedTrace Logo

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

NCT01941836 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 349

Last updated 2019-03-29

No results posted yet for this study

Summary

The purpose of this research study is to see how ETC-1002 is tolerated in the body, to measure the amount of ETC-1002 in the blood, and to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine in patients with elevated LDL-cholesterol with or without statin intolerance.

Conditions

Interventions

DRUG

ETC-1002

Patients receive ETC-1002

DRUG

Ezetimibe

Patients receive ezetimibe

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Esperion Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Diane E MacDougall, MS · Esperion Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-10-31
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01941836 on ClinicalTrials.gov